Israeli biopharma firm Omnix Medical nets $25m series C

[ad_1]

Israeli biopharma firm Omnix Medical has announced a successful €25 million ($25 million) Series C funding round, led by Israeli investment firm Harel Insurance & Finance, along with the European Innovation Council (EIC) Fund. This significant infusion of capital aims to accelerate the development and clinical testing of Omnix’s innovative anti-infective therapies designed to combat multidrug-resistant bacterial infections.

Founded in 2015, Omnix specializes in engineered antimicrobial peptides (AMPs), focusing on rapidly destroying bacterial…

[ad_2]

Source link